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Volume 57, Number 1 Abstracts 283Long-Term Comparison of Thoracic Endovascular Aortic Repair
(TEVAR) to Open Surgery for the Treatment of Thoracic Aortic
Aneurysms
Desai ND, Burtch K, Moser W, et al. J Thorac Cardiovasc Surg 2012;144:
604-11.
Conclusions: Thoracic endovascular aortic repair (TEVAR) is a safe
and effective treatment for thoracic aortic aneurysms. TEVAR provides
improved perioperative results and similar long-term results as open thoracic
aortic repair. TEVAR-treated aneurysms initially decrease in diameter and
then stabilize over time.
Summary: Early clinical results with TEVAR have generally shown a
trend toward better perioperative survival and less major perioperative
complications than open thoracic aortic aneurysm repair. The early results of
the pivotal trials used to gain approval of the Gore TAG, Medtronic Talent,
and Cook Zenith TX2 stent grafts provided highly favorable midterm data
for stent grafts. Longer-term data are still desirable, however. The authors
investigated long-term survival and freedom from aortic complications in
patients enrolled in five U.S. Food and Drug Administration investigational
device exemption studies of TEVAR grafts from a single center and com-
pared them with a group of open control patients with similar anatomic
features. Demographic, clinical, and radiographic parameters were collected
prospectively from patients enrolled in trials assessing the Gore TAG (55),
Medtronic Talent (36), and Cook TX2 (15) devices. Outcomes in patients
treated with these stent grafts were compared with 45 contemporaneous
open controls. From 1995 to 2007, there were 106 patients enrolled in
TEVAR trials at the hospital of the University of Pennsylvania and 45 open
controls. TEVAR patients were older and had more comorbidities, includ-
ing diabetes and renal failure. TEVAR patients had 2.3  1.3 devices
implanted. Mortality (2.6% TEVAR, 6.7% open; P  .1) and paralysis/
paraparesis (3.9% TEAVR, 7.1% open; P  .2) did not differ in the open vs
TEVAR patients. Prolonged intubation 24 hours was more common in
the open controls (9% TEVAR, 24% open; P .002). Overall survival at 8 to
10 years was 40% and was similar between groups (log-rank P  .5).
Predictors of late mortality included age, diabetes, chronic renal failure, and
chronic obstructive coronary disease. Use of TEVAR vs open surgery did not
influence mortality (hazard ratio, 0.9; 95% confidence interval, 0.4-1.6). At
5 years in the TEVAR group, mean aortic diameter decreased from 61 to 55
mm. Freedom from reintervention of the treated segment was 85% in
TEVAR patients at 10 years.
Comment: The article highlights the fact that compared with the
number of patients in whom TEVAR has been performed, the number of
patients with long term follow-up is still relatively small. (The University of
Pennsylvania group has reported 500 TEVAR procedures in other arti-
cles.) In the discussion after the article, Dr Craig Miller from Stanford
indicates that he is concerned that “the entire thoracic field is being ‘dumbed
down’ as the TEVAR era evolved.” One can easily extrapolate Dr Miller’s
concerned to all endovascular techniques “dumbing down” all of vascular
surgery. In the long run, however, outcomes rather than nostalgia will drive
practice patterns in the treatment of vascular disease.
Nationwide Trends and Regional/Hospital Variations in Open Versus
Endovascular Repair of Thoracoabdominal Aortic Aneurysms
Liao JM, Bakeen FG, Cornwell L.D. J Thorac Cardiovasc Surg 2012;144:
612-6.
Conclusions: Use of thoracic endovascular aortic repair (TEVAR) for
thoracoabdominal aortic aneurysm (TAAA) repair has increased signifi-
cantly. Rates of open thoracoabdominal repair have, however, remained
relatively stable. Patients otherwise not surgical candidates, or who did not
otherwise meet traditional surgical indications for open thoracoabdominal
repair, are those most commonly treated with TEVAR for thoracoabdomi-
nal aneurysm repair. This occurs most commonly in regions or hospitals
where open thoracoabdominal repair is less often performed.
Summary: TAAA is an infrequent but highly complex disease with
high perioperative morbidity and mortality rates. Perioperative mortality
rates for TAAA, even in experienced centers, range from 4% to 16%. Given
the morbidity and mortality associated with open TAAA repair, potentially
less morbid procedures using TEVAR with adjunctive surgical visceral vessel
debranching (hybrid approach) or TEVAR with specialized branch en-
dografts have emerged as alternatives to open TAAA repair. The authors
sought to determine regional and hospital variation in use of TEVAR for
treatment of TAAA using the Nationwide Inpatient Sample Database from
2002 to 2005. They attempted to identify all patients with a diagnosis of
TAAA who were treated with a TEVAR-based technique or standard open
thoracoabdominal aortic repair. Procedures were compared between years,
across regions and between hospitals of various sizes. The rate of open
thoracoabdominal aortic repair remained relatively stable (range, 7.5/100
patients in 2005 to 10.1/100 patients in 2008; P .26), whereas the rate of
TEVAR-assisted repairs increased dramatically (range, 1.4/100 patients in
2005 to 6.3/100 patients in 2008; P  .0001). In 2008, 29% of all
TEVAR-based procedures and 11% of all open thoracoabdominal aneurysm
repairs were performed in western regions of the United States (P  .03).
s
nmaller hospitals performed 13% of all TEVAR-based thoracoabdominal
rocedures and 3% of all open thoracoabdominal aneurysm repairs (P 
0001).
Comment: I am not sure anyone should be surprised by the fact that
here may be regional variation in the performance of surgical procedures.
he bigger question is not whether regional variation of surgical procedures
xists but whether regionalization of complex procedures should eventually
e mandated. If regionalization is mandated, how far should patients be
equired to travel for their care and how much additional expense should
heir family entail to be with their family member during the course of the
rocedure? The authors correctly emphasize concerns for patient safety, but
ersonal, logistic, and economic issues also considerably muddy the waters.
osterior Versus Anterior Circulation Infarction: How Different Are
he Neurological Deficits?
ao WD, Liu M, Fisher M, et al. Stroke 2012;43:2060-5.
Conclusion: Symptoms/signs typical of posterior circulation infarc-
ion occur less often than expected. Inaccurate location of deficits will occur
ommonly if clinicians rely only on clinical assessment of neurologic deficits
o differentiate posterior cerebral infarction (PCI) from anterior cerebral
nfarction (ACI).
Summary: Clinical decisions affecting management of cerebral infarc-
ion are often based on associations between symptoms and stenosis in
pecific vascular territories. The Oxfordshire Community Stroke Project has
sed a simple clinical scheme to distinguish PCI fromACI. Classic brainstem
nd cerebellar symptoms were used for identifying PCI (Wardlaw JM et al,
Neurol 1996;243:274-9). Recent magnetic resonance imaging (MRI)
uggests clinical manifestations of PCI and ACI are more alike than dissim-
lar (Fan FQ, Chin J, Stroke 2010;5:730-4, and Searls DE et al, Arch Neurol
012;69:346-51). A comparison of symptoms and signs associated with
maging determined ACI and PCI in a large series of acute stroke patients
as not been previously performed. The authors compared the distribution
f clinical findings between PCI and ACI in patients with MRI-confirmed
erebral infarctions. They also determined diagnostic values of specific
ymptoms and signs for PCI. Neurologic deficits were reviewed and com-
ared in 1174 consecutive patients in the Oxfordshire stroke registry with a
iagnosis of PCI or ACI. Lesions were localized by MRI. The diagnostic
alue of specific symptoms and signs for PCI was determined by measuring
ensitivity, specificity, positive predictive value (PPV), and odds ratios (OR).
omolateral hemiplegia (PCI, 53.6% vs ACI, 74.9%; P  .001), central
acial lingual-based palsy (PCI, 40.7% vs ACI, 62.2%; P  .001), and
emisensory deficits (PCI, 36.4% vs ACI, 34.2%; P  .479) were the three
ost common symptoms and signs in PCI and ACI. Signs with the highest
redictive value favoring the diagnosis of PCI were Horner syndrome (4% vs
%; PPV, 100%; OR, 4; P  .001), cross-sensory deficits (3% vs 0%; PPV,
00%; OR, 4; P  .001), quadrantanopia (1.3% vs 0%; PPV, 100%; OR 4;
 .01), oculomotor nerve palsy (4% vs 0%; PPV, 100%; OR, 4; P .001),
nd cross-motor deficits (4% vs 0.1%; PPV, 92.3%; OR, 36; P  .001).
Comment: The study indicates localization of cerebral infarction by
linical criteria alone is inadequate to reliably distinguish PCI from ACI.
ecause decisions to perform a surgical or catheter-based intervention can be
ased on the anatomic location of the cerebral infarction, neuroimaging is
ital to ensure accurate localization of the cerebral infarction and therefore
ptimal determinations of therapy for patients with a cerebral infarction.
herapy for a cerebral infarction should not be instituted without neuroim-
ging to ensure the accurate localization of the cerebral infarction.
isk of Falls and Major Bleeds in Patients on Oral Anticoagulation
herapy
onze J, Clair C, Hug B, et al. Am J Med 2012;125:773-8.
Conclusion: In patients on oral anticoagulation, high fall risk does not
ave a significantly increased risk of major bleeds. Fall risk is not a valid
eason to avoid oral anticoagulants.
Summary: Many conditions are treated with anticoagulation therapy.
he most common reason for not providing oral anticoagulation where it is
therwise indicated is fall risk (Man-Son-Hing M, Laupacis A, Arch Intern
ed 2003;163:1580-6). However, there are actually scant data addressing
he question of whether high fall risk is associated with major bleeds in
atients receiving oral anticoagulation. Prospective studies of anticoagulants
ften exclude patients with fall risk, and thus, the data on this important
linical question have primarily been derived from limited retrospective
tudies or in specific subpopulations of patients such as those with atrial
brillation. In the article presented here, the authors prospectively studied
onsecutive adult medical patients discharged on oral anticoagulants. The
rimary outcome was the time to first major bleed within a 12-month
ollow-up period adjusted for age, sex, alcohol abuse, number of drugs,
oncomitant treatment with antiplatelet agents, and history of stroke or
ransient ischemic attack. Risk of falls was assessed using two validated
creening questions: Did you fall during the last year? If not, then did you
otice any problemwith gate, balance, or mobility? Patients answering yes to
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January 2013284 Abstractsat least one screening question were considered at high risk for falls, and all
others were considered low risk for falls. This was based on the fact that
previous data have indicated patients who have fallen in the past year would
have a positive likelihood ratio of future falls ranging from 2.3 to 2.8, and
patients who have not fallen in the past year but who had gate, balance, or
mobility problems would have a positive likelihood ratio of future falls
ranging from 1.7 to 2.4 (Ganz DA, JAMA 2007;297:77-86). Of 515
patients enrolled, 35 had a first major bleed during follow-up (incidence rate
of 7.5/100 patient-years). There were 308 patients (59.8%) who were at
high risk of falls, and these patients had a nonsignificantly higher crude
incidence rate of major bleeding than patients at low risk of falls (8.0 vs
6.8/100 patient-years, P .64).Withmultivariate analysis, high fall risk was
not statistically associated with the risk of a major bleed (hazard risk, 1.09;
95% confidence interval, 0.54-2.21). Only three major bleeds occurred
directly after a fall, for an incidence rate of 0.6/100 patient-years.
Comment: The obvious criticism of this study is that patients consid-
ered at high fall risk by their physicians may never have been eligible for
enrollment in this study because decisions may have been made to withhold
anticoagulants in such patients. A second potential weakness is that the
screening questions may overestimate risk of falls. Also, the investigators did
not actually count the total number of falls that occurred during follow-up.
Finally, patients with severe cognitive impairment, who are arguably also at
high risk of falls, were excluded from the study. However, one cannot argue
with the fact that only threemajor bleeds occurred directly after a known fall.
Perhaps a better conclusion would be that falls themselves are over empha-
sized as a risk factor for major bleeds in patients on anticoagulants.
The Effects of Lowering LDL Cholesterol with Statin Therapy in
People at Low Risk of Vascular Disease: Meta-Analysis of Individual
Data from 27 Randomised Trials
Cholesterol Treatment Trialist (CTT) Collaborators. Lancet 2012;380:
581-90.
Conclusion: In patients at low risk of vascular disease, the benefit of
statin therapy in lowering low-density lipoprotein (LDL) cholesterol greatly
exceeds known hazards of statin therapy. Present guidelines for statin
therapy may need to be reconsidered.
Summary: In a previous analysis by the Cholesterol Treatment Trialist
(CTT) collaboration, reduction of LDL cholesterol with statins in subjects
with no previous history of vascular disease reduced the risk of major vascular
events by one-fifth (Cholesterol Treatment Trialist [CTT] Collaboration,
S
tancet 2010:376:1670-81). However, there was uncertainty whether statin
herapy was of overall net benefit in primary prevention (Taylor F, et al,
ochrane Database Syst Rev 2012;1:CD004816). The current meta-analy-
is was designed to evaluate the net effects of cholesterol reduction in
atients at low risk of vascular events. Individual participant data from 22
rials of statins vs controls were used. There were 134,537 individual
articipants (mean LDL cholesterol difference of 1.08 mmol/L; median
ollow-up, 4.8 years). There were five trials of more vs less statin medication,
9,612 participants with a mean LDL cholesterol difference of 0.51
mol/L, and a mean follow-up of 5.1 years. Major vascular events or major
oronary events were defined as nonfatal myocardial infarction, coronary-
elated death, stroke, or coronary revascularization. Participants on control
herapy (no statin or low-intensity statin) were separated into five categories
f baseline 5-year major vascular event risk (5%, 5% to 10%, 10% to
20%, 20% to 30%, and 30%). In each category, the rate ratio (RR) for
ach 1.0-mmol/L LDL cholesterol reduction was estimated. Reduction of
DL cholesterol with statins reduced the risk of major vascular events (RR,
.79; 95% confidence interval [CI], 0.77-0.81 per 1.0-mmol/L reduction).
his was largely independent of age, sex, baseline LDL cholesterol, or
revious vascular disease. The reduction in major vascular events was at least
s big in the two lowest risk categories as in the higher risk categories. There
ere significant reductions in the two lowest risk categories for coronary
vents (RR, 0.57; 99% CI, 0.36-0.89; P  .0012, and RR, 0.61; 99% CI,
.50-0.74; P .0001) and in coronary revascularizations (RR, 0.52; 99%CI
.35-0.75; and RR, 0.63; 99% CI, 0.51-0.79; P  .0001). With regard to
troke, the reduction in risk for participants with a10% 5-year risk of major
ascular events was also similar to that seen in higher risk categories. Statins
educed the risk of vascular mortality (RR per 1.0-mmol/L LDL cholesterol
eduction, 0.85; 95% CI, 0.77-0.95) and all-cause mortality (RR per 1.0
mol/-LDL cholesterol reduction, 0.91; 95%CI, 0.85-0.97). Proportional
eductions were similarly stratified for baseline risk. There was no evidence
hat a reduction in LDL cholesterol with a statin increased the incidence of
ancer, cancer mortality, or other nonvascular mortality.
Comment: Statins appear to be effective and safe for people with a
10% 5-year risk of vascular events. Whereas some data indicate statins are
ssociated with a small excess of hemorrhagic strokes and an increase in
iabetes, the data presented here suggest any long-term effects of small
xcesses of hemorrhagic strokes or diabetes associated with statin therapy are
verwhelmed by statin-dependent reductions in cardiovascular events.
trong consideration needs to be given to rewriting guidelines of cholesterol
herapy for primary prevention of vascular disease.
